Bosch R., Snelder N. Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight. PAGE 2023 [Link to publication]
Bosch R., Snelder N. Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity. ACoP 2022. [Link to publication]
Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J.G., Hoefman S., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol, 2021. [Link to publication]
Bosch R. Successful prediction of continuous glucose dynamics and HbA1c response to the GLP-1 and glucagon co-agonist cotadutide using the 4GI- HbA1c systems model The G lucose- G LP-1- G lucagon- G IP- I nsulin ( 4GI ) model. ASCPT 2021. (poster and lecture)
Bosch R., Petrone M.,Hoefman S., Arends R., Vicini P., Snelder N. Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. WCDT 2019. [Link to publication]
Bosch R., Petrone M., Hoefman S., Arends R., Vicini P., Snelder N. Predicting the effect of GLP-1 agonists on glucose and HbA1c with a 4GI-HbA1c modelo. ACOP, 2019. [Link to publication]
Bosch R., Petrone M., Vicini P., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. PAGE, 2018. [Link to publication]
Stringer F., DeJongh J., Enya K., Koumura E., Danhof M. and Kaku K., Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin for Pioglitazone in Japanese Patients with Type 2 Diabetes, Diabetes Technol Ther, 22: 22, 2014. [Link to publication]
Stringer F., Matsuno K., Snelder N. and Hirayama M., A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients. PAGE.(2013) [Link to publication]
Stringer F., DeJongh J., Scott G. and Danhof M., A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. PAGE.(2013) [Link to publication]